White House approves new COVID-19 vaccine standards after FDA publishes them anyway

FDA Commissioner Stephen Hahn and Trump
(Image credit: Mandel Ngan/AFP/Getty Images)

The White House on Tuesday, in an apparent reversal, approved stringent new Food and Drug Administration guidelines for emergency use approval of a COVID-19 vaccine. The Trump administration was widely reported to have rejected the new guidelines Monday night, citing purported opposition from drugmakers and questioning whether the new standards were necessary. But President Trump had openly criticized the guidelines, which, now in force, will make it difficult but not impossible for a vaccine to get approval before Election Day.

The White House cleared the new standards shortly after the FDA unilaterally published them as part of its briefing materials for an upcoming meeting of its outside vaccine advisory committee, The Washington Post reports. Pfizer also endorsed the guidelines earlier on Tuesday, becoming the last U.S.-backed drugmaker with a late-stage vaccine to publicly signal support. The new standards aren't notably different from other vaccine approval standards, and the FDA created them in part to raise public confidence in COVID-19 vaccines amid politicization from the White House.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.